BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition

Tyrosine kinase inhibitors (TKI) are widely used to treat patients with leukemia driven by BCR-ABL11 and other oncogenic tyrosine kinases2,3. Recent efforts focused on the development of more potent TKI that also inhibit mutant tyrosine kinases4,5. However, even effective TKI typically fail to eradi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Duy, Cihangir, Hurtz, Christian, Shojaee, Seyedmehdi, Cerchietti, Leandro, Geng, Huimin, Swaminathan, Srividya, Klemm, Lars, Kweon, Soo-mi, Nahar, Rahul, Braig, Melanie, Park, Eugene, Kim, Yong-mi, Hofmann, Wolf-Karsten, Herzog, Sebastian, Jumaa, Hassan, Koeffler, H Phillip, Yu, J. Jessica, Heisterkamp, Nora, Graeber, Thomas G., Wu, Hong, Ye, B. Hilda, Melnick, Ari, Müschen, Markus
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3597744/
https://ncbi.nlm.nih.gov/pubmed/21593872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09883
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares